Inspira Technologies Plans Expansion Into Liquid Biopsy Diagnostics Through Proposed Acquisition And Equity Investment

Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today outlines its strategic vision and proposed transaction framework for its planned expansion into liquid biopsy diagnostics, outlining a structured approach designed to preserve shareholder value while enabling future dividend distributions the Company's core respiratory and life-support technologies. This framework underpins a proposed acquisition of an advanced liquid biopsy platform alongside a concurrent equity investment (the "Equity Investment"), positioning Inspira to pursue long-term growth while protecting and monetizing the value of its existing business.

Tal Parnes, Chairman of the Board of Inspira Technologies, stated: "The contemplated acquisition of this liquid biopsy platform represents a significant value inflection point for Inspira, adding a high-impact diagnostics capability with substantial long-term potential. The Board and management have deliberately structured this transaction to pursue this growth opportunity while optimally allocating value between the new platform and Inspira's core respiratory business through a CVR framework. We view this as disciplined, strategic value creation designed to maximize upside across both platforms."

The proposed acquisition represents a natural and execution-ready expansion of Inspira's core competencies in blood-based diagnostics and real-time monitoring. Inspira has built significant proprietary know-how in blood analysis through the development of its HYLA™ blood sensor platform, which utilizes advanced optical sensing and AI-powered algorithms and achieved between 95% to 99% accuracy across measured parameters in clinical testing. The Company proactively established a dedicated blood diagnostics laboratory as foundational infrastructure to support expansion into adjacent diagnostic applications, including oncology. The Company's infrastructure, combined with Inspira's proven track record in navigating the U.S. Food and Drug Administration (FDA) regulatory pathways, exemplified by the 510(k) clearance of the ART100 system, positions the Company to efficiently accelerate the regulatory and commercial advancement of the liquid biopsy technology.